REGENXBIO (NASDAQ:RGNX) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of REGENXBIO (NASDAQ:RGNX) from a hold rating to a sell rating in a research report released on Saturday morning,Wall Street Zen reports.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of REGENXBIO in a research report on Monday, September 28th. Barclays lowered REGENXBIO from an “overweight” rating to a “hold” rating in a research report on Friday, August 7th. UBS Group restated a “positive” rating on shares of REGENXBIO in a research note on Friday. Mizuho set a $18.00 target price on REGENXBIO in a research report on Friday. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $18.00 target price on shares of REGENXBIO in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, REGENXBIO presently has an average rating of “Moderate Buy” and a consensus target price of $23.18.

REGENXBIO Stock Performance

RGNX stock opened at $7.62 on Friday. The stock’s 50 day moving average price is $7.80 and its 200 day moving average price is $9.06. The firm has a market cap of $503.02 million, a P/E ratio of -2.37 and a beta of 1.24. REGENXBIO has a 1 year low of $5.45 and a 1 year high of $16.19.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.67. REGENXBIO had a negative return on equity of 203.98% and a negative net margin of 113.85%. The firm had revenue of $9.16 million during the quarter, compared to analysts’ expectations of $10.89 million. On average, research analysts predict that REGENXBIO will post -3.26 earnings per share for the current year.

Institutional Investors Weigh In On REGENXBIO

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of REGENXBIO in the 2nd quarter valued at approximately $76,641,000. Bank of America Corp DE acquired a new stake in shares of REGENXBIO during the 2nd quarter valued at approximately $6,212,000. Corient Private Wealth LP bought a new position in REGENXBIO during the second quarter worth $2,608,000. Deutsche Bank AG bought a new position in REGENXBIO during the second quarter worth $2,490,000. Finally, Walleye Capital LLC bought a new position in REGENXBIO during the second quarter worth $2,441,000. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.